These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8857548)

  • 21. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
    Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
    Jamieson GP; Finch LR; Snook M; Wiley JS
    Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
    Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
    Tanaka M
    Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1-beta-D-arabinofuranosyl cytosine in a human T-lymphoblastic cell line.
    Verschuur AC; Van Gennip AH; Leen R; Voûte PA; Brinkman J; Van Kuilenburg AB
    Int J Cancer; 2002 Apr; 98(4):616-23. PubMed ID: 11920624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Plunkett W; Dixon DO
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of DNA polymerase inhibitors on repair of gamma ray-induced DNA damage in proliferating (intact versus permeable) human fibroblasts: evidence for differences in the modes of action of aphidicolin and 1-beta-D-arabinofuranosylcytosine.
    Mirzayans R; Enns L; Cubitt S; Karimian K; Radatus B; Paterson MC
    Biochim Biophys Acta; 1994 Oct; 1227(1-2):92-100. PubMed ID: 7918688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
    Braess J; Jahns-Streubel G; Schoch C; Haase D; Haferlach T; Fiegl M; Voss S; Kern W; Schleyer E; Hiddemann W
    Br J Haematol; 2001 Jun; 113(4):975-82. PubMed ID: 11442492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
    Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
    Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
    Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
    Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism of 4'-thio-beta-D-arabinofuranosylcytosine in CEM cells.
    Parker WB; Shaddix SC; Rose LM; Waud WR; Shewach DS; Tiwari KN; Secrist JA
    Biochem Pharmacol; 2000 Dec; 60(12):1925-32. PubMed ID: 11108809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous determination of 1-β-d-Arabinofuranosylcytosine and two metabolites, 1-β-d-Arabinofuranosyluracil and 1-β-d-Arabinofuranosylcytosine triphosphate in leukemic cell by HPLC-MS/MS and the application to cell pharmacokinetics.
    Liang D; Wang W; Jiang X; Yin S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():14-19. PubMed ID: 24880220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
    Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.